Targeting Breast Carcinoma with Radioiodinated Anti-HER2 Nanobody

Overview

Journal Nucl Med Biol

Publisher Elsevier

Specialties Biology
Nuclear Medicine

Date 2012 Nov 20

PMID 23159171

Citations 56

Authors

Marek Pruszynski

Eftychia Koumarianou

Ganesan Vaidyanathan

Hilde Revets

Nick Devoogdt

Tony Lahoutte

Michael R Zalutsky

Affiliations

Soon will be listed here.

Abstract

Introduction: With a molecular weight an order of magnitude lower than antibodies but possessing comparable affinities, Nanobodies (Nbs) are attractive as targeting agents for cancer diagnosis and therapy. An anti-HER2 Nb could be utilized to determine HER2 status in breast cancer patients prior to trastuzumab treatment. This provided motivation for the generation of HER2-specific 5F7GGC Nb, its radioiodination and evaluation for targeting HER2 expressing tumors.

Methods: 5F7GGC Nb was radioiodinated with ¹²⁵I using Iodogen and with ¹³¹I using the residualizing agent N(ɛ)-(3-[¹³¹I]iodobenzoyl)-Lys⁵-N(α)-maleimido-Gly¹-GEEEK ([¹³¹I]IB-Mal-D-GEEEK) used previously successfully with intact antibodies. Paired-label internalization assays using BT474M1 cells and tissue distribution experiments in athymic mice bearing BT474M1 xenografts were performed to compare the two labeled Nb preparations.

Results: The radiochemical yields for Iodogen and [¹³¹I]IB-Mal-D-GEEEK labeling were 83.6±5.0% (n=10) and 59.6±9.4% (n=15), respectively. The immunoreactivity of labeled proteins was preserved as confirmed by in vitro and in vivo binding to tumor cells. Biodistribution studies showed that Nb radiolabeled using [¹³¹I]IB-Mal-D-GEEEK, compared with the directly labeled Nb, had a higher tumor uptake (4.65±0.61% ID/g vs. 2.92±0.24% ID/g at 8h), faster blood clearance, lower accumulation in non-target organs except kidneys, and as a result, higher concomitant tumor-to-blood and tumor-to-tissue ratios.

Conclusions: Taken together, these results demonstrate that 5F7GGC anti-HER2 Nb labeled with residualizing [¹³¹I]IB-Mal-D-GEEEK had better tumor targeting properties compared to the directly labeled Nb suggesting the potential utility of this Nb conjugate for SPECT (¹²⁹I) and PET imaging (¹²⁴I) of patients with HER2-expressing tumors.

Citing Articles

Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.

Vanermen M, Ligeour M, Oliveira M, Gestin J, Elvas F, Navarro L EJNMMI Radiopharm Chem. 2024; 9(1):69.

PMID: 39365487 PMC: 11452365. DOI: 10.1186/s41181-024-00298-4.

Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies.

Haji Abdolvahab M, Karimi P, Mohajeri N, Abedini M, Zare H Cancer Cell Int. 2024; 24(1):67.

PMID: 38341580 PMC: 10858526. DOI: 10.1186/s12935-024-03259-8.

Extracellular targeted protein degradation: an emerging modality for drug discovery.

Wells J, Kumru K Nat Rev Drug Discov. 2023; 23(2):126-140.

PMID: 38062152 DOI: 10.1038/s41573-023-00833-z.

Single domain Camelid antibody fragments for molecular imaging and therapy of cancer.

Li S, Hoefnagel S, Krishnadath K Front Oncol. 2023; 13:1257175.

PMID: 37746282 PMC: 10514897. DOI: 10.3389/fonc.2023.1257175.

Improvement of the Effectiveness of HER2+ Cancer Therapy by Use of Doxorubicin and Trastuzumab Modified Radioactive Gold Nanoparticles.

Zelechowska-Matysiak K, Salvanou E, Bouziotis P, Budlewski T, Bilewicz A, Majkowska-Pilip A Mol Pharm. 2023; 20(9):4676-4686.

PMID: 37607353 PMC: 10481397. DOI: 10.1021/acs.molpharmaceut.3c00414.

References

Foulon C, Welsh P, Bigner D, Zalutsky M . Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. Nucl Med Biol. 2001; 28(7):769-77. DOI: 10.1016/s0969-8051(01)00239-6. View

Gainkam L, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I . Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008; 49(5):788-95. DOI: 10.2967/jnumed.107.048538. View

Scholl S, Beuzeboc P, Pouillart P . Targeting HER2 in other tumor types. Ann Oncol. 2001; 12 Suppl 1:S81-7. DOI: 10.1093/annonc/12.suppl_1.s81. View

Zalutsky M, Colcher D, Kaplan W, Kufe D . Radioiodinated B6.2 monoclonal antibody: further characterization of a potential radiopharmaceutical for the identification of breast tumors. Int J Nucl Med Biol. 1985; 12(3):227-33. DOI: 10.1016/0047-0740(85)90030-0. View

Miao Y, Fisher D, Quinn T . Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues. Nucl Med Biol. 2006; 33(6):723-33. DOI: 10.1016/j.nucmedbio.2006.06.005. View

Shankar S, Vaidyanathan G, Affleck D, Peixoto K, Bigner D, Zalutsky M . Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. Nucl Med Biol. 2004; 31(7):909-19. DOI: 10.1016/j.nucmedbio.2004.04.007. View

Behe M, Kluge G, Becker W, Gotthardt M, Behr T . Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med. 2005; 46(6):1012-5. View

Kakar S, Puangsuvan N, Stevens J, Serenas R, Mangan G, Sahai S . HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000; 5(3):199-207. DOI: 10.1054/modi.2000.16690. View

Mather S, McKenzie A, Sosabowski J, Morris T, Ellison D, Watson S . Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med. 2007; 48(4):615-22. PMC: 2246928. DOI: 10.2967/jnumed.106.037085. View

10.

Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn Jr P . Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984; 72(1):77-89. DOI: 10.1016/0022-1759(84)90435-6. View

11.

Gainkam L, Caveliers V, Devoogdt N, Vanhove C, Xavier C, Boerman O . Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging. 2010; 6(2):85-92. DOI: 10.1002/cmmi.408. View

12.

Reist C, Archer G, Wikstrand C, Bigner D, Zalutsky M . Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 1997; 57(8):1510-5. View

13.

Foulon C, Reist C, Bigner D, Zalutsky M . Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res. 2000; 60(16):4453-60. View

14.

Revets H, De Baetselier P, Muyldermans S . Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther. 2005; 5(1):111-24. DOI: 10.1517/14712598.5.1.111. View

15.

Shankar S, Vaidyanathan G, Affleck D, Welsh P, Zalutsky M . N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs. Bioconjug Chem. 2003; 14(2):331-41. DOI: 10.1021/bc025636p. View

16.

Harmsen M, De Haard H . Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 2007; 77(1):13-22. PMC: 2039825. DOI: 10.1007/s00253-007-1142-2. View

17.

Huang L, Muyldermans S, Saerens D . Nanobodies®: proficient tools in diagnostics. Expert Rev Mol Diagn. 2010; 10(6):777-85. DOI: 10.1586/erm.10.62. View

18.

Tran T, Engfeldt T, Orlova A, Sandstrom M, Feldwisch J, Abrahmsen L . (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem. 2007; 18(6):1956-64. DOI: 10.1021/bc7002617. View

19.

Mume E, Orlova A, Larsson B, Nilsson A, Nilsson F, Sjoberg S . Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug Chem. 2005; 16(6):1547-55. DOI: 10.1021/bc050056o. View

20.

Ekblad T, Tran T, Orlova A, Widstrom C, Feldwisch J, Abrahmsen L . Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging. 2008; 35(12):2245-55. DOI: 10.1007/s00259-008-0845-7. View